RECURRENT BREAST CARCINOMA

This early-phase trial tests a DNA vaccine called STEMVAC in 42 people with advanced HER2-negative breast cancer. The vaccine aims to train the immune system to attack cancer stem cells, which are resistant to standard treatments. The study focuses on safety and whether the vacci…

This study tests if a form of estrogen called estradiol can help people with a specific type of triple negative breast cancer that has spread. The cancer must have a protein called ER beta, which may make tumors grow slower when exposed to estrogen. The goal is to see if the trea…

This study tests whether combining an immunotherapy drug (avelumab) with other medications can help shrink or control advanced triple-negative breast cancer that has spread or cannot be removed by surgery. About 145 adults with stage IV or recurrent triple-negative breast cancer …

This phase 3 trial tested whether adding the drug entinostat to standard hormone therapy (exemestane) helps people with advanced hormone receptor-positive breast cancer live longer without their cancer growing. The study included 608 adults whose breast cancer had spread locally …

This study tests two drug combinations (olaparib plus either vistusertib or capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The goal is to find the safest dose and see if the drugs can control tumor growth. About 159 adults…

This study tests two hormone therapies, tamoxifen and a newer drug called z-endoxifen, in postmenopausal women with a type of advanced breast cancer (ER+/HER2-). The goal is to see which one better delays cancer growth. About 81 women who have already tried an aromatase inhibitor…

This early-stage trial tests a combination of two drugs, cyclophosphamide and veliparib, in 35 people with HER2-negative breast cancer that has spread or cannot be removed by surgery. The goal is to find the safest dose and see how well the drugs work together to stop tumor growt…

This early-phase study tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than …

This early-phase trial tests the safety and best doses of two drugs (bevacizumab and temsirolimus) given alone or with other medicines (valproic acid or cetuximab) in people with advanced cancer or certain non-cancerous diseases that are hard to treat. The goal is to find the hig…

This early-phase trial tested a drug called Z-endoxifen in 62 women with estrogen receptor-positive (ER+) breast cancer that had spread or come back. The main goal was to find the safest dose and understand side effects. Z-endoxifen works by blocking estrogen, which can fuel brea…

This study tests whether adding a drug called copanlisib to the usual two-drug therapy (fulvestrant and abemaciclib) works better for people with a certain type of advanced breast cancer (hormone receptor-positive, HER2-negative) that has spread. About 24 participants will receiv…

This early-phase study tests a new combination of two drugs—veliparib and carboplatin—in people with HER2-negative breast cancer that has spread. The goal is to find the safest dose and see if the combo can shrink tumors. About 44 adults with advanced or returning breast cancer w…

This study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to standard therapy are enrolled. The goal is to see if targe…

This study looks at whether doctors can consistently measure the chemotherapy drug paclitaxel in the blood of cancer patients. The goal is to see if this could help adjust doses to kill cancer while reducing nerve damage, a common side effect. About 22 adults with various solid t…

This study aims to create a large collection of blood and tumor samples from 300 people whose breast cancer has spread or returned. By linking these samples with medical information, researchers hope to learn why the cancer spreads and why people respond differently to treatments…